| FOLFIRINOX (n = 168) | Gemcitabine (n = 66) | P-value |
---|---|---|---|
Mean age + SD | 64 ± 9.55 | 75 ± 8.76 | < 0.01 |
Performance status score 2–3 (%) | 8 (5) | 11 (17) | < 0.01 |
Mean BMI + SD | 23.5 ± 3.81 | 23.5 ± 4.41 | ns |
Weight loss > 5% body weight * (%) | 110 (65) | 50 (76) | ns |
Diabetes (%) | 10 (6) | 5 (7.5) | ns |
Back pain (%) | 108 (64) | 44 (67) | ns |
Serum CA 19–9 level* (IU) (+SD) | 3884 ± 13,137 | 1743 ± 4916 | ns |
Tumour location (%) | Â | Â | ns |
 Head | 117 (70) | 44 (65) |  |
 Body | 40 (24) | 17 (26) |  |
 Tail | 11 (6) | 5 (9) |  |
Tumour classification (%) | Â | Â | ns |
 Borderline | 116 (69) | 42 (64) |  |
 Locally advanced | 52 (31) | 24 (36) |  |
Arterial invasion (%) | 68 (40.5) | 25 (38) | ns |